155 related articles for article (PubMed ID: 38070051)
1. Single-cell analysis extracted CAFs-related genes to established online app to predict clinical outcome and radiotherapy prognosis of prostate cancer.
Lai C; Wu Z; Li Z; Huang X; Hu Z; Yu H; Yuan Z; Shi J; Hu J; Mulati Y; Liu C; Xu K
Clin Transl Oncol; 2024 May; 26(5):1240-1255. PubMed ID: 38070051
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
3. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
4. Single-cell and bulk RNA sequencing reveal cancer-associated fibroblast heterogeneity and a prognostic signature in prostate cancer.
Liu W; Wang M; Wang M; Liu M
Medicine (Baltimore); 2023 Aug; 102(32):e34611. PubMed ID: 37565899
[TBL] [Abstract][Full Text] [Related]
5. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a prognostic risk prediction model incorporating disulfidptosis-related lncRNA for patients with prostate cancer.
Mulati Y; Lai C; Luo J; Hu J; Xu X; Kong D; Xiao Y; Liu C; Xu K
BMC Cancer; 2024 Jan; 24(1):44. PubMed ID: 38191330
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated fibroblast-derived gene signatures predict radiotherapeutic survival in prostate cancer patients.
Zhang R; Liu F
J Transl Med; 2022 Oct; 20(1):453. PubMed ID: 36195908
[TBL] [Abstract][Full Text] [Related]
8. Predicting biochemical-recurrence-free survival using a three-metabolic-gene risk score model in prostate cancer patients.
Zhao Y; Tao Z; Li L; Zheng J; Chen X
BMC Cancer; 2022 Mar; 22(1):239. PubMed ID: 35246070
[TBL] [Abstract][Full Text] [Related]
9. Integration of single-cell RNA-seq and bulk RNA-seq data to construct and validate a cancer-associated fibroblast-related prognostic signature for patients with ovarian cancer.
Shen L; Li A; Cui J; Liu H; Zhang S
J Ovarian Res; 2024 Apr; 17(1):82. PubMed ID: 38627854
[TBL] [Abstract][Full Text] [Related]
10. [Basement membrane-related gene signature to predict biochemical recurrence in patients with prostate cancer after radical prostatectomy].
Wang ZH; Liu Z; Zhao XD; Hu EY; Chen YH; Xu XF; Xia J; Liu YH; Dong J; Xu S; Cheng W
Zhonghua Nan Ke Xue; 2022 Dec; 28(12):1071-1079. PubMed ID: 37846626
[TBL] [Abstract][Full Text] [Related]
11. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
Front Immunol; 2022; 13():947802. PubMed ID: 36405735
[TBL] [Abstract][Full Text] [Related]
12. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
13. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq.
Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z
J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cancer-related fibroblasts (CAF) in hepatocellular carcinoma and construction of CAF-based risk signature based on single-cell RNA-seq and bulk RNA-seq data.
Yu L; Shen N; Shi Y; Shi X; Fu X; Li S; Zhu B; Yu W; Zhang Y
Front Immunol; 2022; 13():1009789. PubMed ID: 36211448
[TBL] [Abstract][Full Text] [Related]
15. Integrative analysis of cancer-associated fibroblast signature in gastric cancer.
Zhao Z; Mak TK; Shi Y; Li K; Huo M; Zhang C
Heliyon; 2023 Sep; 9(9):e19217. PubMed ID: 37809716
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Han C; Deng Y; Yang B; Hu P; Hu B; Wang T; Liu J; Xia Q; Liu X
Front Immunol; 2023; 14():1126902. PubMed ID: 36891298
[TBL] [Abstract][Full Text] [Related]
17. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J
Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418
[TBL] [Abstract][Full Text] [Related]
18. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
19. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence.
Xing Q; Liu S; Luan J; Wang Y; Ma L
Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719
[TBL] [Abstract][Full Text] [Related]
20. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma.
Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ
Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]